← Back to Search

Monoclonal Antibodies

Dato-DXd + Durvalumab for Breast Cancer

Phase 3
Recruiting
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer
ECOG PS of 0 or 1
Must not have
Evidence of distant disease
Known HIV infection that is not well controlled
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely
Awards & highlights

Summary

This trial tests the effectiveness and safety of new treatments for TNBC and hormone receptor-low/HER2-negative breast cancer.

Who is the study for?
Adults over 18 with Stage II or III breast cancer that's triple-negative or hormone receptor-low/HER2-negative can join. They need good bone marrow and organ function, an ECOG performance status of 0 or 1, a tumor sample for testing, and must follow local contraception rules.
What is being tested?
The study compares two treatments: Dato-DXd plus durvalumab (with/without chemo) versus pembrolizumab plus chemotherapy (with/without more chemo), both before and after surgery in patients who haven't had prior treatment for their breast cancer.
What are the potential side effects?
Possible side effects include immune-related reactions, fatigue, nausea, hair loss from chemotherapy drugs like Paclitaxel and Doxorubicin; heart issues from Epirubicin; blood cell count changes; potential kidney damage from Carboplatin.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer is confirmed to be at Stage II or III and is either triple-negative or has low hormone receptors and is HER2-negative.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to parts of my body far from where it started.
Select...
My HIV infection is not well controlled.
Select...
I have an active tuberculosis infection.
Select...
I have had lung inflammation not caused by an infection.
Select...
I have a serious heart condition that is not under control.
Select...
I have had treatment or surgery for triple-negative or low hormone receptor/HER2-negative breast cancer.
Select...
I do not have active or uncontrolled hepatitis B or C.
Select...
I am currently pregnant, breastfeeding, or planning to become pregnant.
Select...
I have a serious eye condition affecting my cornea.
Select...
I do not have an infection needing IV drugs or have an undiagnosed infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of definitive surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of definitive surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Event-free survival (EFS) in the experimental vs control arms
Pathologic Complete Response (pCR) in the experimental vs control arms
Secondary study objectives
Distant disease-free survival (DDFS) in the experimental vs control arms
Immunogenicity of Dato-DXd (in combination with durvalumab)
Overall Survival (OS) in the experimental vs control arms
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Dato-DXd plus durvalumabExperimental Treatment9 Interventions
Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemotherapy may be given in combination with durvalumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease Adjuvant chemotherapy may be one of these: 1. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) and carboplatin (weekly or Q3W) for 4 cycles (12 weeks); 2. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) for 4 cycles (12 weeks); 3. Carboplatin (weekly or Q3W) + paclitaxel (weekly) for 4 cycles (12 weeks); 4. Capecitabine (Q3W) for 8 cycles.
Group II: Pembrolizumab plus chemotherapyActive Control8 Interventions
Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Adjuvant capecitabine (Q3W) for 8 cycles may be given in combination with pembrolizumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Epirubicin
2012
Completed Phase 4
~19470
Durvalumab
2017
Completed Phase 2
~3840
Doxorubicin
2012
Completed Phase 3
~8030
Cyclophosphamide
2010
Completed Phase 4
~2320
Paclitaxel
2011
Completed Phase 4
~5810
Carboplatin
2014
Completed Phase 3
~6120
Capecitabine
2013
Completed Phase 3
~3970
Olaparib
2007
Completed Phase 4
~2190

Find a Location

Who is running the clinical trial?

Daiichi Sankyo, Inc.Industry Sponsor
389 Previous Clinical Trials
420,872 Total Patients Enrolled
27 Trials studying Breast Cancer
17,911 Patients Enrolled for Breast Cancer
AstraZenecaLead Sponsor
4,352 Previous Clinical Trials
288,645,081 Total Patients Enrolled
175 Trials studying Breast Cancer
1,243,850 Patients Enrolled for Breast Cancer
Daiichi SankyoIndustry Sponsor
401 Previous Clinical Trials
445,332 Total Patients Enrolled
25 Trials studying Breast Cancer
15,936 Patients Enrolled for Breast Cancer
~1152 spots leftby Mar 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top